Exposure to Alendronate is Associated with a Lower Risk of Bone Metastases in Osteoporotic Women with Early Breast Cancer
Conclusions: History of alendronate use is associated with a lower likelihood of bone metastases in postmenopausal women with early breast cancer. Oral bisphosphonate treatment could be sufficient for reducing the risk of bone metastases.
Source: Journal of Bone Oncology - Category: Cancer & Oncology Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | History of Medicine | Men | Menopause | Oral Cancer | Orthopaedics | Osteoporosis | Study | Women